Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapy
3.3. Snippet by End User
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing clinical trial for colorectal cancer drugs
4.1.2. Restraints
4.1.2.1. The high costs of drugs for colorectal cancer
4.1.3. Opportunity
4.1.3.1. Growing focus on developing targeted therapies that specifically address the molecular characteristics
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
8.4. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
8.5. BRAF Or MEK Inhibitors
8.6. Tyrosine Kinase (TKI) Inhibitors
8.7. Immunomodulators
8.8. Others
9. By Therapy
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
9.1.2. Market Attractiveness Index, By Therapy
9.2. Immunotherapy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Targeted therapy
9.4. Chemotherapy
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospital*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Research Institute
10.5. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.7.1. The U.S.
12.2.7.2. Canada
12.2.7.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.7.1. Germany
12.3.7.2. The U.K.
12.3.7.3. France
12.3.7.4. Italy
12.3.7.5. Spain
12.3.7.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.7.1. Brazil
12.4.7.2. Argentina
12.4.7.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.7.1. China
12.5.7.2. India
12.5.7.3. Japan
12.5.7.4. Australia
12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Genentech, Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Eli Lilly and Company
14.3. Pfizer
14.4. Sanofi S.A.
14.5. Bristol-Myers Squibb
14.6. Amgen
14.7. Merck & Co., Inc.
14.8. Teva Pharmaceuticals
14.9. Novartis
14.10. GlaxoSmithKline
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us